The presence of a handful of companies in the global market for
exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics
has rendered the vendor landscape largely consolidated and mildly
competitive, observes Transparency Market Research in a new report.
Companies contributing to the global EPI therapeutics and diagnostics
market are mostly concentrated in Europe and North America.
Some of the leading companies in the market are Nordmark Arzneimittel
GmbH & Co. KG, AbbVie, Inc., Cilian AG, Digestive Care, Inc.,
Janssen Pharmaceuticals, Inc., Anthera Pharmaceuticals, Inc.,
Allergan plc, and AzurRx BioPharma, Inc.
According to the report, the global market for exocrine pancreatic
insufficiency (EPI) therapeutics and diagnostics was valued at
US$3,397.5 mn in 2016 and is estimated to reach US$6,414.4 mn by
2025, registering a CAGR of 7.2% from 2017 to 2025.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2748
Of the key diagnostics tests used for diagnosing EPI, including
computerized tomography (CT) scanning, magnetic resonance imaging
(MRI), endoscopic ultra-sonography (EUS), and blood tests, the
segment of CT scanning presently accounts for the dominant share in
terms of revenue contribution to the global market. The segment is
likely to remain the most in-demand modality for EPI diagnosis in the
years to come, albeit lose some grounds owing to the easy
availability of other more sensitive techniques such as MRI.
Geographically, the North America market accounts for a significant
share in the overall market owing to the large patient pool and a
rising prevalence of cystic fibrosis and diabetes. The region is
likely to remain the top contributor to the global market in terms of
diagnostics technologies, new drugs, and revenue.
Request a Brochure of the Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2748
One of the key factors contributing to the positive growth prospects
of the global EPI therapeutics and diagnostics market presently is
the astronomical rise in the number of people suffering from
diabetes. Diabetes is known to be the key factor leading to an
increased tendency of patients contracting cystic fibrosis and
chronic pancreatitis, the two key factors that lead to EPI. According
to the American Diabetes Association, the world will have nearly 366
mn diabetics by 2030.
Furthermore, studies show that nearly 90% of the people with cystic
fibrosis end up having EPI. A high number of people suffering from
chronic pancreatitis also develop EPI. According the Cystic Fibrosis
Foundation, nearly 30,000 people in the U.S. alone and around 70,000
across the globe have cystic fibrosis. Nearly 1,000 new cases of the
condition are diagnosed each year in the U.S. Owing to the alarming
increase in the prevalence of cystic fibrosis, the risk of EPI also
increases substantially.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2748
The stringent approval and sales regulations pertaining to drugs and
therapeutics across regions such as North America and Europe could
severely affect the overall growth prospects of the global EPI
therapeutics and diagnostics market to a certain extent. These
regulations stifle the market by making it difficult for several
players to penetrate into the market. Nevertheless, the vast set of
growth opportunities offered by the rising pool of diabetics across
emerging economies. Countries especially from Asia Pacific have a
great scope of adoption of a variety of EPI therapeutics and
diagnostic products owing to the rising expenditure on healthcare,
high-paced development of the healthcare infrastructure, and the
rising patient pool of EPI.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment